CION Ameerpet
Intraperitoneal chemotherapy puts the drug where ovarian cancer actually lives — into the abdominal cavity itself, through a port, instead of only into a vein. It has genuine trial evidence behind it and genuine practical drawbacks, and it is offered to a narrow group of women rather than to everyone.
Ovarian cancer does not usually travel through the bloodstream first. It sheds cells into the fluid of the abdominal cavity, and those cells settle on the surfaces they drift against — the peritoneal lining, the omentum, the outside of the bowel, the underside of the diaphragm. Intraperitoneal chemotherapy is built around that single fact. If the disease lives on those surfaces, put the drug there.
In intravenous chemotherapy the drug enters a vein, circulates through the whole body, and reaches the abdominal lining at whatever concentration survives the journey. In intraperitoneal chemotherapy a soft catheter is placed into the abdominal cavity during surgery and tunnelled to a port under the skin over the lower ribs. On treatment day, one to two litres of fluid carrying the drug is run in through that port and left to bathe the peritoneal surfaces. The lining absorbs it slowly, so the concentration sitting against the tumour deposits is many times higher than a vein could deliver, while comparatively less reaches the rest of the body.
Women searching ip chemotherapy ovarian cancer are usually deciding between this and standard intravenous treatment, often within days of debulking surgery, and often with very little time to read. The honest summary is that intraperitoneal chemotherapy is not simply a stronger version of chemotherapy. It is a demanding option with good evidence in one specific situation, and the situation matters more than the technique.
Into the peritoneal cavity through an implanted catheter and port, rather than into a vein. Most regimens combine the two — some drugs given intraperitoneally, some intravenously, within the same cycle.
The peritoneal lining absorbs slowly. That lets a far higher drug concentration sit against surface tumour deposits, for longer, than the bloodstream can achieve — the peritoneal-plasma barrier working in the patient's favour.
Mainly women with stage III epithelial ovarian cancer whose surgery removed all visible disease or left deposits under 1 cm. Bulky residual disease is the wrong setting: the drug penetrates only a few millimetres into tumour.
Intraperitoneal chemotherapy has strong trial evidence behind it and a stubborn practical problem in front of it. In GOG-172, women with optimally debulked stage III ovarian cancer who received intraperitoneal rather than intravenous chemotherapy lived longer — but fewer than half completed all six planned intraperitoneal cycles. Catheter blockage, catheter infection, abdominal pain and toxicity, rather than the cancer itself, were what stopped treatment. That one finding explains most of what has happened to intraperitoneal chemotherapy in the twenty years since. Source: Armstrong DK et al., New England Journal of Medicine (2006); NCCN Clinical Practice Guidelines, Ovarian Cancer.
Yes — in the population it was tested in, with caveats that have grown larger over two decades. Both halves of that sentence deserve equal weight when you are the one deciding.
Three randomised trials run by the Gynecologic Oncology Group compared intraperitoneal with intravenous platinum-based chemotherapy in women whose stage III disease had been optimally debulked. Each found longer survival in the intraperitoneal arm, and the largest of them, GOG-172, was convincing enough that intraperitoneal treatment entered international guidelines and has stayed there.
The caveats matter as much as the result. Toxicity was markedly worse — more abdominal pain, more nausea and vomiting, more fatigue, more infection, more nerve damage and more disturbance of blood salts. Catheters blocked, leaked and became infected, and fewer than half of the women in GOG-172 finished all six intraperitoneal cycles. A treatment that only half of patients can complete is a different proposition from one that most people tolerate.
Practice has also moved on. GOG-252 compared intraperitoneal and intravenous regimens when anti-angiogenic therapy was added to every arm, and found no advantage in progression-free survival for the intraperitoneal groups. Many women now have chemotherapy before surgery rather than only after it, which is not the setting the original trials studied. And PARP-inhibitor-class maintenance therapy, which did not exist when those trials ran, has changed outcomes in its own right. Intraperitoneal chemotherapy is therefore used far less often than it was a decade ago, and where it is used it is chosen deliberately, one patient at a time.
Longer survival with intraperitoneal treatment in women with optimally debulked stage III disease, across three randomised trials. That finding is real and has never been withdrawn.
Substantially more toxicity, and a completion rate below half in the largest trial. Treatment mostly stopped because of catheter problems and side effects, not because the cancer had progressed.
Anti-angiogenic treatment, maintenance therapy and the shift towards chemotherapy before surgery have all altered the comparison. Guidelines still list intraperitoneal chemotherapy; far fewer centres now use it.
*No page can tell you what any treatment will do for you individually. Trial results describe groups of women chosen to fit narrow entry criteria — the useful question in clinic is whether you resemble those women closely enough for the result to transfer.
These three are confused constantly, including in clinic. They differ in where the drug goes, how many times it is given, whether it is heated, and who delivers it.
| Feature | IV chemotherapy | IP chemotherapy | HIPEC |
|---|---|---|---|
| Where the drug goes | Into a vein, then around the whole body | Into the abdominal cavity through an implanted port | Into the abdominal cavity in the operating theatre |
| How often | Usually six cycles, roughly every three weeks | Usually six cycles, with drug instilled on two days of each cycle | Once only, during the operation |
| Is it heated? | No | No — instilled at body temperature | Yes — circulated warm for about 60–90 minutes |
| Needs surgery? | No — a vein or a chest port is enough | Yes — a peritoneal catheter placed during an operation | Yes — it is part of the operation itself |
| Usual setting | Any stage, before or after surgery | Stage III disease left with minimal visible tumour after debulking | At interval debulking, after chemotherapy has shrunk the disease |
| Main drawback | Systemic side effects; lower drug levels at the peritoneal surfaces | Abdominal pain, catheter problems, and cycles often abandoned early | A longer operation and recovery; offered at relatively few centres |
| Where CION stands | Delivered in-house, across 35+ centres | Coordinated with specialist partner centres, where the port and the delivery sit | Coordinated with partner centres — see HIPEC for ovarian cancer |
*Regimens differ between centres. What matters more than the label is whether your surgery left minimal visible disease, because every one of these approaches depends on that.
Bring your operative note, histopathology report and current treatment plan. A 45-minute consultation is enough to say plainly whether intraperitoneal treatment is a real option in your case — or whether it is not, and what is.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and takes 45 minutes. If intraperitoneal chemotherapy would not help in your situation, we will say so and explain what would.
If this is being offered to you, here is what the next four to five months look like in practice — and the points at which the plan commonly changes.
The catheter is a soft tube that sits inside the abdominal cavity. It is tunnelled under the skin to a small port over the lower ribs, which is where a needle goes on treatment day. It is almost always placed during the debulking operation itself, because that is when the abdomen is already open and because the surgeon only knows whether intraperitoneal treatment makes sense once cytoreduction is complete.
This is the part that makes intraperitoneal chemotherapy a coordinated rather than an in-house service. The port is placed by the gynaecologic-oncology surgical team at a specialist partner centre, and the intraperitoneal cycles are given where that team and that catheter are. Ask at the outset who will manage the port, and where you go if it blocks.
Expect a long day rather than a short one. Blood counts and kidney function are checked first. Intravenous fluid is given before the instillation to protect the kidneys, along with anti-sickness medication. A needle is placed into the port, and one to two litres of fluid carrying the drug is run in over roughly half an hour to an hour.
The abdomen feels full, tight and heavy while the fluid is in. Most women describe pressure and bloating rather than sharp pain, and it eases over the following day or two as the fluid is absorbed. You will be asked to change position from time to time so the fluid reaches all the surfaces. Fluid is given afterwards as well, so a treatment day commonly runs to six hours or more.
A standard course is six cycles, three weeks apart, with drug given on two separate days within each cycle — one intraperitoneal, one intravenous, or a combination, depending on the regimen your centre uses. On paper it is four to five months.
In practice, a substantial proportion of women do not finish all six intraperitoneal cycles, and that is an expected outcome rather than a failure. When treatment is switched to the intravenous route partway through, the remaining cycles still count. Knowing this in advance takes a great deal of the sting out of it if it happens to you.
Intraperitoneal chemotherapy carries every side effect of intravenous chemotherapy — low blood counts, infection risk, nausea, fatigue, hair loss, tingling in the hands and feet — and adds abdominal ones. Abdominal pain and distension during and after instillation are the most common, along with more pronounced nausea and vomiting, and disturbance of blood salts such as magnesium and potassium.
Catheter problems form the second group: blockage, infection at the port site, leakage of fluid into the abdominal wall, and occasionally bowel injury or adhesions that make instillation impossible. Report fever, worsening abdominal pain, redness over the port, or fluid tracking under the skin the same day rather than waiting for your next visit. Managing these well is the difference between finishing the course and abandoning it.
The common triggers are a catheter that will not run or has become infected, abdominal pain that is not controlled between cycles, kidney function that has dropped, persistently low blood counts, or nerve symptoms that are worsening. Any of these is a reason to change route, and none of them means the cancer has done anything.
In most cases treatment then continues intravenously to the end of the planned course, at full effect. Your oncologist should tell you before each cycle what would make them switch, so that it does not arrive as a shock in the middle of treatment.
Intraperitoneal chemotherapy is not appropriate where surgery has left bulky residual disease, because the drug penetrates only a few millimetres and cannot reach the middle of a deposit. It is also avoided where extensive adhesions would stop fluid distributing evenly, where the bowel has been extensively resected or a stoma raises the risk of injury, and where kidney function or general fitness are borderline.
Age alone is not a reason to rule it out, but tolerance genuinely matters here more than with intravenous treatment, and a frank conversation about what you can and cannot cope with over four to five months is part of the assessment rather than an afterthought.
Ask four things. Did my surgery leave visible disease, and if so how much? What does this centre's own experience with intraperitoneal cycles look like — how many women complete the course? Who manages the port between cycles, and where do I go at nine at night if something goes wrong with it? And what is the alternative plan, in full, if we do not do this?
Ask about cost separately and in writing, because intraperitoneal cycles are given at the centre where the port was placed and are usually billed there. If you want a second view before committing, that is entirely reasonable — the complete guide to ovarian cancer is a useful starting point, and a free second opinion is quicker to arrange than most people assume.
Intraperitoneal chemotherapy is a coordinated service at CION, not an in-house one, and it is worth saying that before you travel for an opinion. The catheter goes in during an operation, and the intraperitoneal cycles are given where that catheter and the team who placed it are. CION coordinates intraperitoneal chemotherapy, HIPEC, all ovarian cancer surgery and PET-CT with specialist gynaecologic-oncology surgeons at partner centres, and treatment delivered there may also be billed there.
What CION delivers itself is the part you will spend the most months with. Intravenous chemotherapy for ovarian cancer and maintenance therapy are given in-house across 35+ centres in Telangana and Andhra Pradesh, so cycles and follow-up can happen near where you live rather than requiring a trip into the city every three weeks. BRCA and HRD testing and genetic counselling are in-house too, as are nutrition support and survivorship follow-up.
The first consultation is free and runs about 45 minutes — long enough to read your operative note and histopathology properly, which is what actually decides whether intraperitoneal treatment is on the table at all. Every case that raises a question goes to a tumour board rather than to one doctor's judgement. If the answer is that intraperitoneal chemotherapy would not help you, you will be told that plainly, with the reasoning, and shown the treatment options that would.
Free, unhurried, and long enough to go through the operative note and pathology that decide whether intraperitoneal treatment is even possible in your case.
Medical oncology, imaging, pathology and the coordinating surgical team review the plan together, rather than one clinician deciding the route of delivery alone.
Chemotherapy and maintenance therapy are ours. Surgery, HIPEC, intraperitoneal delivery and PET-CT sit with partner centres, and we say so before you commit rather than after.
Intravenous cycles, blood counts and follow-up can be delivered close to home across Telangana and Andhra Pradesh, which matters over a four-to-five-month course.
*Intraperitoneal chemotherapy, HIPEC, ovarian cancer surgery and PET-CT are delivered at specialist partner centres and may be billed there. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up are delivered by CION.
Intraperitoneal chemotherapy delivers the drug straight into the abdominal cavity instead of only into a vein. A soft catheter is placed inside the abdomen during surgery and connected to a port under the skin over the lower ribs. On treatment day, one to two litres of fluid carrying the drug is run in through that port and left to bathe the peritoneal surfaces, where ovarian cancer deposits sit. Because the lining absorbs slowly, the concentration against those deposits is far higher than intravenous treatment can achieve. Most regimens still combine intraperitoneal and intravenous drugs within the same cycle rather than replacing one with the other.
In one specific situation, trials showed it was. Three randomised trials in women with stage III ovarian cancer whose surgery had removed all or almost all visible disease found longer survival with intraperitoneal treatment. Outside that situation the evidence does not support it, and even inside it the picture has changed. Intraperitoneal treatment caused considerably more abdominal pain, nausea, infection and nerve damage, and fewer than half the women in the largest trial completed all six intraperitoneal cycles. A later trial found no progression-free survival advantage once anti-angiogenic therapy was given to everyone. So the answer depends entirely on how much disease your surgery left behind, and on what else is in your treatment plan.
A needle is placed into the port under the skin, and the fluid carrying the drug runs in over roughly half an hour to an hour. Most women describe pressure, fullness and bloating rather than sharp pain — the abdomen genuinely is full of a litre or more of fluid, and you will be asked to shift position so it reaches all the surfaces. The tightness eases over the following day or two as the fluid is absorbed. Abdominal discomfort in the days after a cycle is common and is treated with regular pain relief. Pain that is severe, worsening, or comes with fever or redness over the port needs to be reported the same day.
Both put chemotherapy into the abdominal cavity, but almost everything else differs. HIPEC is given once, in the operating theatre, immediately after the surgeon has removed visible disease, and the drug is heated and circulated through the abdomen for about an hour before the operation is closed. Intraperitoneal chemotherapy is given repeatedly, over several cycles across four to five months, through an implanted port, at body temperature, in a day-care unit. HIPEC is a surgical event; intraperitoneal chemotherapy is a course of treatment. Both are coordinated with specialist partner centres rather than delivered in-house at CION.
It is not appropriate when surgery has left bulky residual disease, because the drug penetrates only a few millimetres and cannot reach the centre of a larger deposit. It is also avoided where extensive adhesions would prevent fluid spreading evenly through the abdomen, after extensive bowel surgery or where a stoma increases the risk of injury, and where kidney function, blood counts or general fitness are borderline. Ongoing abdominal infection rules it out. Age by itself does not, but tolerance matters more here than with intravenous treatment, so an honest conversation about what you can cope with over four to five months is part of the assessment.
The first consultation is free and runs about 45 minutes. Intraperitoneal chemotherapy is coordinated rather than delivered in-house: the catheter is placed during gynaecologic-oncology surgery at a specialist partner centre, the intraperitoneal cycles are given where that catheter and team are, and treatment there may also be billed there. We say this upfront rather than leaving it to be discovered later. What CION delivers itself is intravenous chemotherapy and maintenance therapy, across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing, nutrition support and follow-up. Every case that raises a question is reviewed at a tumour board.